Full Press Release Details
ALX Oncology Realigns Executive Leadership Team.
ALXO
ALX Oncology Realigns Executive Leadership Team
Key Takeaway: ALX Oncology Realigns Executive Leadership Team
Price reaction · baseline $4.55 (2023-09-05 close) · hit after-hours · clean, no other ALXO news in the window
day 0 close
+6.4%
day 1 · peak
+9.2%
day 3
+9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)